Invasion-Block is designed to measure the invasive capacity of cancer cells, enabling scientists to assess how well various drugs can prevent the spread of cancer.
Australian yeast innovation experts MicroBioGen will be presenting at the 37th International Specialised Symposium on Yeasts conference being held in Adelaide.
While the trial was designed to test safety and not efficacy, patients treated with Araclon Biotech’s experimental ABvac40 vaccine saw a 38% drop in disease progression compared to placebo.
Researchers developed a proof-of-concept model for delivering gene editing tools to treat blood disorders, allowing for the modification of diseased blood cells directly within the body.